

## Valeant Pharmaceuticals International Inc (VRX) - Financial and Strategic SWOT Analysis Review

URL:	<a href="https://marketpublishers.com/r/VE656B9CD2CEN.html">https://marketpublishers.com/r/VE656B9CD2CEN.html</a>
Date:	April 4, 2018
Pages:	68
Price:	US\$ 125.00
ID:	VE656B9CD2CEN

Valeant Pharmaceuticals International Inc (VRX) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company's businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company's key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

- Business description – A detailed description of the company's operations and business divisions.
- Corporate strategy – Analyst's summarization of the company's business strategy.
- SWOT Analysis – A detailed analysis of the company's strengths, weakness, opportunities and threats.
- Company history – Progression of key events associated with the company.
- Major products and services – A list of major products, services and brands of the company.
- Key competitors – A list of key competitors to the company.
- Key employees – A list of the key executives of the company.
- Executive biographies – A brief summary of the executives' employment history.
- Key operational heads – A list of personnel heading key departments/functions.
- Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
- Key manufacturing facilities – A list of key manufacturing facilities of the company.
- Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

### Highlights

Valeant Pharmaceuticals International Inc (Valeant) develops, manufactures and markets several branded, over-the-counter (OTC) and generic drugs. The company also offers medical devices such as medical contact lenses, intraocular lenses, ophthalmic surgical equipment, and aesthetics devices. Valeant offers products in the areas of dermatology, neurology, eye health and branded generics. It offers a diverse mix of products in various regions across the world including the US, Canada, Australasia, Latin America, and Central and Eastern Europe. The company has manufacturing facilities in Canada, Mexico, the US and countries in Europe, North Africa, Asia and South America. Valeant is headquartered in Laval, Quebec, Canada.

### Valeant Pharmaceuticals International Inc Key Recent Developments

Feb 28,2018: Valeant Announces Fourth-Quarter And Full-Year 2017 Financial Results

Nov 15,2017: Bausch + Lomb Helps To Recycle More Than One Million Units Of Contact Lens Materials Within First Year Of Launching The ONE By ONE Recycling Program

Nov 07,2017: Valeant Announces Third-Quarter 2017 Results

Sep 15,2017: Valeant Commits \$200,000 to Support Hurricane Relief Efforts

Sep 05,2017: Québec Superior Court Grants Leave under Québec Securities Act in Valeant Pharmaceuticals Securities Class Action

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors' business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.

- The company's core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.

- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies' strategic, financial and operational performance.

- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.

- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

**Note:** Some sections may be missing if data is unavailable for the company

## Table of Content

### SECTION 1 - ABOUT THE COMPANY

Valeant Pharmaceuticals International Inc - Key Facts  
Valeant Pharmaceuticals International Inc - Key Employees  
Valeant Pharmaceuticals International Inc - Key Employee Biographies  
Valeant Pharmaceuticals International Inc - Major Products and Services  
Valeant Pharmaceuticals International Inc - History  
Valeant Pharmaceuticals International Inc - Company Statement  
Valeant Pharmaceuticals International Inc - Locations And Subsidiaries  
Head Office

Other Locations & Subsidiaries

## **SECTION 2 – COMPANY ANALYSIS**

Company Overview

Valeant Pharmaceuticals International Inc - Business Description

Business Segment: Bausch + Lomb/International

Overview

Performance

Key Stats

Business Segment: Branded Rx

Overview

Performance

Business Segment: US Diversified Products

Overview

Performance

Geographical Segment: Australia

Performance

Geographical Segment: Brazil

Performance

Geographical Segment: Canada

Performance

Geographical Segment: China

Performance

Geographical Segment: Egypt

Performance

Geographical Segment: France

Performance

Geographical Segment: Germany

Performance

Geographical Segment: Japan

Performance

Geographical Segment: Mexico

Performance

Geographical Segment: Others

Performance

Geographical Segment: Poland

Performance

Geographical Segment: Russia

Performance

Geographical Segment: The UK

Performance

Geographical Segment: The US and Puerto Rico

Performance

R&D Overview

Valeant Pharmaceuticals International Inc - Corporate Strategy

Valeant Pharmaceuticals International Inc - SWOT Analysis

SWOT Analysis - Overview

Valeant Pharmaceuticals International Inc - Strengths

Valeant Pharmaceuticals International Inc - Weaknesses

Valeant Pharmaceuticals International Inc - Opportunities

Valeant Pharmaceuticals International Inc - Threats

Valeant Pharmaceuticals International Inc - Key Competitors

## **SECTION 3 – COMPANY FINANCIAL RATIOS**

Financial Ratios - Capital Market Ratios  
Financial Ratios - Annual Ratios  
Performance Chart  
Financial Performance  
Financial Ratios - Interim Ratios  
Financial Ratios - Ratio Charts

## **SECTION 4 – COMPANY’S LIFESCIENCES FINANCIAL DEALS AND ALLIANCES**

Valeant Pharmaceuticals International Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018  
Valeant Pharmaceuticals International Inc, Pharmaceuticals & Healthcare, Deals By Type, 2012 to YTD 2018  
Valeant Pharmaceuticals International Inc, Recent Deals Summary

## **SECTION 5 – COMPANY’S RECENT DEVELOPMENTS**

Nov 15, 2017: Bausch + Lomb Helps To Recycle More Than One Million Units Of Contact Lens Materials Within First Year Of Launching The ONE By ONE Recycling Program  
Nov 07, 2017: Valeant Announces Third-Quarter 2017 Results  
Sep 15, 2017: Valeant Commits \$200,000 to Support Hurricane Relief Efforts  
Sep 05, 2017: Québec Superior Court Grants Leave under Québec Securities Act in Valeant Pharmaceuticals Securities Class Action  
Aug 16, 2017: Valeant Receives FDA Confirmation Of Voluntary Action Indicated Inspection Classification For Tampa Facility  
Aug 08, 2017: Valeant Announces Second-Quarter 2017 Results  
Jun 22, 2017: Bausch + Lomb Named Most Trusted Contact Lens Solution Brand In Canada For Second Consecutive Year By Brandspark International  
Jun 22, 2017: Bausch + Lomb Named Most Trusted Contact Lens Solution Brand In Canada For Second Consecutive Year By Brandspark International  
Jun 19, 2017: Valeant Appoints Arthur J. Shannon As Senior Vice President, Head Of Investor Relations And Communications  
Jun 19, 2017: John Paulson Joins Valeant Board Of Directors

## **SECTION 6 – APPENDIX**

Methodology  
Ratio Definitions  
About GlobalData  
Contact Us  
Disclaimer

## **LIST OF TABLES**

Valeant Pharmaceuticals International Inc, Key Facts  
Valeant Pharmaceuticals International Inc, Key Employees  
Valeant Pharmaceuticals International Inc, Key Employee Biographies  
Valeant Pharmaceuticals International Inc, Major Products and Services  
Valeant Pharmaceuticals International Inc, History  
Valeant Pharmaceuticals International Inc, Other Locations  
Valeant Pharmaceuticals International Inc, Subsidiaries  
Valeant Pharmaceuticals International Inc, Key Competitors  
Valeant Pharmaceuticals International Inc, Ratios based on current share price  
Valeant Pharmaceuticals International Inc, Annual Ratios

Valeant Pharmaceuticals International Inc, Annual Ratios (Cont.1)  
Valeant Pharmaceuticals International Inc, Annual Ratios (Cont.2)  
Valeant Pharmaceuticals International Inc, Interim Ratios  
Valeant Pharmaceuticals International Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018  
Valeant Pharmaceuticals International Inc, Pharmaceuticals & Healthcare, Deals By Type, 2012 to YTD 2018  
Valeant Pharmaceuticals International Inc, Recent Deals Summary  
Currency Codes  
Capital Market Ratios  
Equity Ratios  
Profitability Ratios  
Cost Ratios  
Liquidity Ratios  
Leverage Ratios  
Efficiency Ratios

## **LIST OF FIGURES**

Valeant Pharmaceuticals International Inc, Performance Chart (2013 - 2017)  
Valeant Pharmaceuticals International Inc, Ratio Charts  
Valeant Pharmaceuticals International Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018  
Valeant Pharmaceuticals International Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018

## **COMPANIES MENTIONED**

AIM Therapeutics Inc  
Endo International Plc  
GTx Inc  
Maruho Co Ltd  
Mylan NV  
Opiant Pharmaceuticals Inc  
Pfizer Canada Inc  
Polydex Pharmaceuticals Ltd  
Sirona Biochem Corp  
Stratus Pharmaceuticals Inc  
Xenon Pharmaceuticals Inc

### I would like to order:

**Product name:** Valeant Pharmaceuticals International Inc (VRX) - Financial and Strategic SWOT Analysis Review  
**Product link:** <https://marketpublishers.com/r/VE656B9CD2CEN.html>  
**Product ID:** VE656B9CD2CEN  
**Price:** US\$ 125.00 (Single User License / Electronic Delivery)

*If you want to order Corporate License or Hard Copy, please, contact our Customer Service: [office@marketpublishers.com](mailto:office@marketpublishers.com)*

### Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click 'BUY NOW' button on product page <https://marketpublishers.com/r/VE656B9CD2CEN.html>

### To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
E-mail:  
Company:  
Address:  
City:  
Zip/Post Code:  
Country:  
Tel:  
Fax:  
Your message:

\* All fields are required

Customer Signature \_\_\_\_\_

Please, note that by ordering from MarketPublisher.com you are agreeing to our Terms & Conditions at [https://marketpublishers.com/docs/terms\\_conditions.html](https://marketpublishers.com/docs/terms_conditions.html)

To place an order via fax simply print this form, fill in the information below and fax the completed form to **+44 20 7900 3970**